Hopstem is a pharmaceutical company engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.
Hopstem is a Hangzhou-based pharmaceutical company, engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 31, 2021 | Series B | $40M | 1 | — | — | Detail |
May 27, 2021 | Series A | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lilly Asia Ventures | — | Series B |
Longmen Capital | — | Series A |